Global Finance News
22 Dec 2025, 14:29
Galapagos Reports Mixed Phase 3-Enabling Results for TYK2 Inhibitor GLPG3667
Galapagos said its selective TYK2 inhibitor GLPG3667 met the primary endpoint in a Phase 3-enabling study in dermatomyositis, showing statistically significant clinical benefit versus placebo, along with meaningful improvements on secondary measures and a consistent safety profile. In a separate Phase 3-enabling study in systemic lupus erythematosus, the drug did not achieve statistical significance on the primary endpoint, although numerical improvements were observed on several secondary endpoints. Galapagos said it will evaluate strategic options, including potential partnering, to accelerate further development of GLPG3667 in dermatomyositis and possibly other severe autoimmune diseases.
Galapagos said its selective TYK2 inhibitor GLPG3667 met the primary endpoint in a Phase 3-enabling study in dermatomyositis, showing statistically significant clinical benefit versus placebo, along with meaningful improvements on secondary measures and a consistent safety profile. In a separate Phase 3-enabling study in systemic lupus erythematosus, the drug did not achieve statistical significance on the primary endpoint, although numerical improvements were observed on several secondary endpoints. Galapagos said it will evaluate strategic options, including potential partnering, to accelerate further development of GLPG3667 in dermatomyositis and possibly other severe autoimmune diseases.